@FierceBiotech: From FierceBiotechIT.com: IMS Health scoops up Incential Software. Report | Follow @FierceBiotech
@RyanMFierce: Sanofi seeks compelling case for next-generation Lantus in diabetes war. Article | Follow @RyanMFierce
@EmilyMFierce: Spinal muscular atrophy patients could benefit from new drug. Story | Follow @EmilyMFierce
> The U.S. Securities and Exchange Commission has sued ex-InterMune ($ITMN) Controller Bruce Tomlinson for allegedly disclosing secret information about the drug Esbriet to a former business associate. Story
> Boston-based Follica may have found the answer to baldness. News
> Eli Lilly ($LLY) has so far created 7 Project Focused Companies, or PFCs, in its Capital Funds Portfolio. Blog
> Puma Biotechnology ($PBYI) has begun a Phase III clinical trial of its lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer. Release
@FierceMedDev: Don't forget to nominate! We're looking for 15 of the fiercest device and diagnostics developers. Info | Follow @FierceMedDev
@DamianFierce: Study: Medical devices spur complications for kids. More | Follow @DamianFierce
@MarkHFierce: Teleflex has long pursued M&A involving small startups with promising tech. This time, it's Israel's Eon Surgical. Article | Follow @MarkHFierce
@MichaelGFierce: BioFire scores CE mark for sepsis blood Dx. Item | Follow @MichaelGFierce
> Bayer closes $1.1B birth control device deal. Article
> Mobisante reels in $4.2M to market its ultrasound mobile app. Story
> Quest allies with Hologic in women's health Dx deal. News
Pharma News
@FiercePharma: Mini-Pfizer? Endo to cut 700 jobs, review asset sales in refocus on core pharma biz. Yesterday's story | Follow @FiercePharma
@EricPFierce: Is Teva and its generic of Avandia the big winner in today's vote? More | Follow @EricPFierce
@CarlyHFierce: The FDA advisory panel reached a verdict on Avandia yesterday. How would you have voted? Story | Follow @CarlyHFierce
> Battle of weight-loss drugs begins as Arena launches Belviq next week. Article
> Sanofi uses multi-pronged strategy to defend its place in diabetes market. Story
> Reuters: Forest, Icahn negotiate to avoid 3rd proxy battle. More
And Finally… Despite the lingering economic crisis, the French biotech sector is showing some signs of life. More